
Cardiometabolic Medicine
The need for consistent updates and agile content is imperative for today’s clinician to remain current on the continuum of scientific data. In no therapeutic area is this more essential than in “Cardiometabolic Medicine,” a new term meant to encompass the interconnected and debilitating diagnoses of diabetes mellitus, heart failure, coronary artery disease/acute coronary syndrome, progressive renal insufficiency, and related disorders such as hypertension, hyperlipidemia, and hyperkalemia. These areas are subject to frequent pivotal trial publications, guidelines updates, FDA action, and outcomes assessments.
Our Tweetorials
Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.
Q & A About HCM: Guidance from the Guidelines
Multidisciplinary Management of the patient with T2D and CKD 3-4
2) This #accredited #tweetorial series on #kidneydisease #CKD is supported by an independent educational grant from the Boehringer Ingelheim/Lilly...
ACC2023 LATE-BREAKING CLINICAL TRIAL UPDATES ON ADVANCES IN MANAGEMENT OF HYPERLIPIDEMIA
1a) Welcome to a two-part (today and Monday) live-tweeted, #accredited #tweetorial on 2⃣ 🔑#LBCTs from @ACCinTouch #ACC23 in #NewOrleans 🥳on advances...
Journal Club: Trends in Use of OACs in Older Adults With Newly Diagnosed AFib, 2010-2020
1b) This is a #journalclub review of an excellent article published in late 2022 in @JAMANetworkOpen 🔓 https://t.co/qoP1gddS4o. 👏to @darae_ko et al...
Anti-FXa DOAC Reversal in Patients with Bleeding After Major Trauma
2) This program is supported by an educational grant from AstraZeneca & is intended for an audience of #healthcare providers. Statement of...
Multidisciplinary Management of the patient with T2D and CKD 1-2
2) This #accredited #tweetorial series on #kidneydisease #CKD is supported by an independent educational grant from the Boehringer Ingelheim/Lilly...
Risk Stratification: Identifying the Patient with T2D and DKD Most at Risk for Rapid Progression to Advanced CKD
2) This #accredited #tweetorial series on #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the...
HCM: Pathophysiology and Optimal Contemporary Medical Management
2) Follow this 🧵for 0.75h 🆓CE/#CME! See prior programs on #HCM, still available for even more 🆓credit, at https://t.co/7KtfmhxQ0v, where you'll find...
Journal Club: Underprescribing vs Underfilling in Oral Anticoagulation for SPAF
1b) This is a #journalclub review of an excellent article published in late 2022 in J Manag Care Spec Pharm 🔓 https://t.co/nKfAvbrmNB.👏to...
MOA and Clinical Trial Data for Novel and Emerging Therapeutic Strategies for HCM: Can We Target Our Therapy?
1b) Our expert (and returning @cardiomet_ce) author is Giuseppe Galati MD, MMSc in Heart Failure, FHFA, @GiuseppeGalati_ , Consultant #Cardiologist...
@Cardiomet_CE on Twitter
Your only source for ACCREDITED SoMe-delivered
serialized professional cardiometabolic education. Physicians, nurses, pharmacists–come one, come all!
On Twitter at @cardiomet_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME. Programs are presented by expert faculty in engaging and fully interactive format. Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.